Status:
UNKNOWN
Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer
Lead Sponsor:
Huazhong University of Science and Technology
Collaborating Sponsors:
Zhejiang University
Wuhan Central Hospital
Conditions:
Uterine Cervical Neoplasms
Cervical Cancer
Eligibility:
FEMALE
18-70 years
Brief Summary
Cervical cancer is one of the major health problems for chinese women. Besides surgery and radiotherapy, neoadjuvant chemotherapy has been proved to be an effective program by many studies. However, ...
Eligibility Criteria
Inclusion
- Untreated cervical cancer with FIGO stage Ib-IIb
- Measurable lesions
- Possible to radical hysterectomy
- Age: 18 and older
- Karnofsky Performance Status≥ 70.
- WBC \> 3,000/mm³, Hb \> 9.0g/dl, Platelet \> 100,000 /mm³, SGOT/SGPT \< 60 IU/L, T-Bil \< 1.5 mg/dL, Cr \< 1.2 mg/dL, PaO2 \> 80 torr, normal ECG
- Written informed consent
Exclusion
- Previous history of cancer
- Patients with previous treatment
- Patients without information of clinical risk factors
- Patients who have active infection
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2020
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT03229187
Start Date
January 1 2016
End Date
September 30 2020
Last Update
June 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital
Wuhan, Hubei, China, 430030